| 1 | 患有斜视眼阵挛-肌阵挛综合征的儿童对ritux-imab的免疫和临床反应显示文摘Opsoclonus-myoclonus syndrome (OMS) is an autoimmune disorder with serious neurodevelopmental morbidity and limited treatment options. We treated a toddler with moderately severe OMS with rituximab, a monoclonal anti-B cell antibody. The patient’s clinical response was documented on videotape and scored with the OMS Evaluation Scale. Cerebrospinal fluid lymphocyte subsets were evaluated by flow-cytometric immunophenotyping, with a comprehensive panel of monoclonal antibodies. Eradication of cerebrospinal fluid B cells, which previously were expanded, was associated with dramatic clinical improvement. There also were secondary changes in other lymphocyte subsets that might be relevant to the clinical response and lack of serious infections. In addition to clarifying the immune response to B-cell depletion, these data reveal a promising new therapy for OMS that warrants a phase I clinical trial. | PranzatelliM.R. Tate E.D. Travelstead A.L. Longee D. 王经纬 | 2006 | 世界核心医学期刊文摘(儿科学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员